AR022382A1 - Composicion farmaceutica, su empleo para preparar un medicamento y su presentacion en forma de un conjunto de piezas individuales (set) - Google Patents

Composicion farmaceutica, su empleo para preparar un medicamento y su presentacion en forma de un conjunto de piezas individuales (set)

Info

Publication number
AR022382A1
AR022382A1 ARP990104617A ARP990104617A AR022382A1 AR 022382 A1 AR022382 A1 AR 022382A1 AR P990104617 A ARP990104617 A AR P990104617A AR P990104617 A ARP990104617 A AR P990104617A AR 022382 A1 AR022382 A1 AR 022382A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
prepare
employment
presentation
individual parts
Prior art date
Application number
ARP990104617A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR022382A1 publication Critical patent/AR022382A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Una composicion farmacéutica que contiene ciclo-(Arg-Gli-Asp-D-Fen-NMe-Val) y/o una de sus sales aceptables desde el punto de vista fisiologico y al menosun compuesto quimioterapéutico y/o una de sus sales aceptables desde el punto de vista fisiologico y/o un inhibidor de la angiogénesis y/o una de sus salesaceptables desde el punto de vista fisiologico. El empleo de la composicion farmacéutica para preparar un medicamento destinado a combatir las enfermedadesangiogénicas patologicas, las trombosis, el infarto de miocardio, las enfermedades coronarias, la arteriosclerosis, los tumores, la osteoporosis, lasinflamaciones e infecciones. Un conjunto de piezas (set) que se compone de envases separados de (a) una cantidad efectiva de ciclo-(Arg-Gli-Asp-D-Fen-NMe-Val)y (b) una cantidad efectiva de un compuesto quimioterapéutico.
ARP990104617A 1998-09-16 1999-09-15 Composicion farmaceutica, su empleo para preparar un medicamento y su presentacion en forma de un conjunto de piezas individuales (set) AR022382A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19842415A DE19842415A1 (de) 1998-09-16 1998-09-16 Pharmazeutische Zubereitung

Publications (1)

Publication Number Publication Date
AR022382A1 true AR022382A1 (es) 2002-09-04

Family

ID=7881169

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990104617A AR022382A1 (es) 1998-09-16 1999-09-15 Composicion farmaceutica, su empleo para preparar un medicamento y su presentacion en forma de un conjunto de piezas individuales (set)
ARP100103356A AR078175A2 (es) 1998-09-16 2010-09-15 Un conjunto de piezas individuales (set)

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP100103356A AR078175A2 (es) 1998-09-16 2010-09-15 Un conjunto de piezas individuales (set)

Country Status (31)

Country Link
US (1) US6683051B1 (es)
EP (2) EP1113809B1 (es)
JP (2) JP2002524526A (es)
KR (1) KR100703253B1 (es)
CN (2) CN1201812C (es)
AR (2) AR022382A1 (es)
AT (2) ATE292470T1 (es)
AU (1) AU765073B2 (es)
BR (1) BR9913737A (es)
CA (1) CA2344151A1 (es)
CO (1) CO5140070A1 (es)
CZ (1) CZ302908B6 (es)
DE (3) DE19842415A1 (es)
DK (2) DK1466615T3 (es)
ES (2) ES2327331T3 (es)
HU (1) HUP0103521A3 (es)
ID (1) ID29226A (es)
IL (2) IL141516A0 (es)
MY (1) MY129572A (es)
NO (1) NO331734B1 (es)
NZ (1) NZ510040A (es)
PE (1) PE20001046A1 (es)
PL (1) PL201902B1 (es)
PT (2) PT1466615E (es)
RU (1) RU2227041C2 (es)
SI (1) SI1113809T1 (es)
SK (1) SK287012B6 (es)
TR (1) TR200100765T2 (es)
TW (1) TW576744B (es)
WO (1) WO2000015244A2 (es)
ZA (1) ZA200103073B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
BR0116575A (pt) * 2001-01-09 2004-01-06 Merck Patent Gmbh Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
WO2003074045A1 (fr) * 2002-03-05 2003-09-12 Eisai Co., Ltd. Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese
DK1734996T3 (da) * 2004-04-02 2013-06-10 Univ California Fremgangsmåder og sammensætninger til behandling og forebyggelse af sygdom, der er associeret med alfa v beta 5-integrin
CN103463630A (zh) * 2005-11-02 2013-12-25 杜克大学 同时的化学疗法和免疫疗法
EP1973569B1 (en) * 2006-01-18 2013-05-22 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
BRPI0815567B8 (pt) 2007-07-17 2021-05-25 Merck Patent Gessellschaft Mit Beschraenkter Haftung anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica
US20100069302A1 (en) 2007-07-18 2010-03-18 Stefan Krueger Specific therapy and medicament using integrin ligands for treating cancer
WO2010051667A1 (zh) * 2008-11-10 2010-05-14 复旦大学 一种环肽纳米管药物组合物及其应用
MX2011005256A (es) * 2008-11-20 2011-05-31 Merck Patent Gmbh Nueva terapia y medicamento que usa liganodos de integrina para tratamiento de cancer.
JP2012528079A (ja) 2009-05-25 2012-11-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためのインテグリンリガンドの連続投与
KR101752515B1 (ko) 2009-07-24 2017-06-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Avb5 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물
PE20121359A1 (es) 2009-12-10 2012-10-15 Merck Patent Gmbh Composicion farmaceutica que comprende oligopeptidos
CA2805338A1 (en) 2010-07-16 2012-01-19 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
WO2012069149A1 (en) 2010-11-23 2012-05-31 Merck Patent Gmbh Solution comprising cyclic oligopeptides
JP6320042B2 (ja) 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 前立腺癌治療のための抗アルファ−vインテグリン抗体
WO2012110200A1 (en) * 2011-02-18 2012-08-23 Merck Patent Gmbh Cyclic peptide cyclo (l -arginyl - glycyl - l -aspartyl - d - phenylalanyl - n-methyl - l -valyl), compositions thereof, and use thereof in methods for treating graft -versus - host disease
ES2720477T3 (es) 2011-06-09 2019-07-22 Merck Patent Gmbh Tratamiento de cánceres y metástasis con suspensiones de Cilengitide en portador
WO2013130775A1 (en) * 2012-03-01 2013-09-06 Dizerega, Gere, S. Methods for treating patients undergoing multi-cycle chemotherapy
CN103333227B (zh) * 2013-06-07 2015-10-07 东南大学 转移肿瘤缺失蛋白小分子环肽抑制剂及其制备方法与应用
US20190242908A1 (en) 2016-09-08 2019-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
JP2019208422A (ja) * 2018-06-04 2019-12-12 コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー ヒアルロニダーゼを含む新規な組換えエキソソーム及びその用途
GB201911816D0 (en) * 2019-08-16 2019-10-02 Univ London Queen Mary Treatment
GB202103122D0 (en) * 2021-03-05 2021-04-21 Univ London Queen Mary Treatment

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04367367A (ja) 1991-06-11 1992-12-18 Nkk Corp ロータリノズル
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
AU701776B2 (en) 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
PL318199A1 (en) 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
JPH10504807A (ja) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
DK0710657T3 (da) 1994-11-02 1999-05-25 Merck Patent Gmbh Adhæsionsreceptor-antagonister
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
DE19548709A1 (de) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosinderivate
JPH09208571A (ja) * 1996-02-02 1997-08-12 Takeda Chem Ind Ltd アルキリデンシクロヘキサン誘導体
WO1997041844A1 (en) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
PL330241A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods of and compositions useful in inhibiting angiogenesis
JPH1081631A (ja) * 1996-07-17 1998-03-31 Takeda Chem Ind Ltd 癌転移または再発抑制剤
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
DE19850131A1 (de) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate

Also Published As

Publication number Publication date
PT1466615E (pt) 2009-09-07
RU2227041C2 (ru) 2004-04-20
NO331734B1 (no) 2012-03-12
ATE292470T1 (de) 2005-04-15
CN100352494C (zh) 2007-12-05
ES2241363T3 (es) 2005-10-16
EP1113809A2 (de) 2001-07-11
MY129572A (en) 2007-04-30
CN1636590A (zh) 2005-07-13
IL141516A (en) 2009-09-22
TW576744B (en) 2004-02-21
JP2011252012A (ja) 2011-12-15
PL348026A1 (en) 2002-05-06
EP1113809B1 (de) 2005-04-06
PL201902B1 (pl) 2009-05-29
CZ2001932A3 (cs) 2001-09-12
AU765073B2 (en) 2003-09-11
NO20011308D0 (no) 2001-03-15
WO2000015244A2 (de) 2000-03-23
CA2344151A1 (en) 2000-03-23
AU5975899A (en) 2000-04-03
CN1201812C (zh) 2005-05-18
WO2000015244A3 (de) 2000-06-22
ZA200103073B (en) 2002-08-21
SK3372001A3 (en) 2001-11-06
ATE432707T1 (de) 2009-06-15
IL141516A0 (en) 2002-03-10
KR100703253B1 (ko) 2007-04-03
DE59911881D1 (de) 2005-05-12
DK1466615T3 (da) 2009-08-31
CZ302908B6 (cs) 2012-01-18
DE59915033D1 (de) 2009-07-16
EP1466615B1 (de) 2009-06-03
AR078175A2 (es) 2011-10-19
CN1329499A (zh) 2002-01-02
DK1113809T3 (da) 2005-08-08
PT1113809E (pt) 2005-08-31
ES2327331T3 (es) 2009-10-28
TR200100765T2 (tr) 2001-08-21
HUP0103521A3 (en) 2002-05-28
NZ510040A (en) 2003-12-19
CO5140070A1 (es) 2002-03-22
PE20001046A1 (es) 2000-10-14
NO20011308L (no) 2001-03-15
SI1113809T1 (en) 2005-10-31
ID29226A (id) 2001-08-16
SK287012B6 (sk) 2009-09-07
HUP0103521A2 (hu) 2002-02-28
EP1466615A1 (de) 2004-10-13
KR20010073155A (ko) 2001-07-31
DE19842415A1 (de) 2000-03-23
US6683051B1 (en) 2004-01-27
JP2002524526A (ja) 2002-08-06
BR9913737A (pt) 2001-06-05

Similar Documents

Publication Publication Date Title
AR022382A1 (es) Composicion farmaceutica, su empleo para preparar un medicamento y su presentacion en forma de un conjunto de piezas individuales (set)
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
ES2128846T3 (es) Utilizacion del fumagilol y sus derivados para preparar los medicamentos destinados a combatir las infecciones intestinales.
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
RU2001110104A (ru) Фармацевтическая композиция, содержащая циклопептид и химиотерапевтическое средство или ингибитор ангиогенеза
AR007160A1 (es) Compuestos antagonistas del receptor de adhesion, procedimiento para preparar estos compuestos y preparaciones farmaceuticas que los contienen
PA8452001A1 (es) Derivados de macrolidos c-4" sustituidos
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
CO5680405A2 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
NO20022058D0 (no) Farmasöytiske sammensetninger
AR007640A1 (es) DERIVADOS DE FENILALANINA, PROCEDIMIENTO PARA PREPARARLOS, PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN Y EMPLEO DE LOS MISMOS PARA PREPARAR UNMEDICAMENTO QUE ACTUA COMO INHIBIDOR DE LA INTEGRINA ALFA(v)
MX9307781A (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos y procedimientos para su preparacion.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
AR006569A1 (es) Derivados de acidos carboxilicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
AR027398A1 (es) Derivados de indol-3-ilo
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
AR010538A1 (es) Composicion farmaceutica para inhibir el desarrollo del cancer de mama en mujeres menopausicas que comprende raloxifeno (6-[hidroxi]-2-(4-hidroxifenil)-benzo (b)-tien-3-il]-4-[-2-(1-piperidinil)etoxi-fenil)]-metanona
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2054333T3 (es) Forma de dosificacion para administrar un antagonista del calcio.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.

Legal Events

Date Code Title Description
FC Refusal